ISTODAX is indicated for Treatment of Peripheral T-Cell Lymphoma (PTCL) in patients who have received at least one prior therapy

INN:

Subtype:

PTCL (PTCL)

License:

FDA

Class:

Histone deacetylase inhibitor

R/R

PIhttp://www.celgene.com/content/uploads/istodax-pi.pdf 

1. Approved Labelling 

ISTODAX is indicated for Treatment of Peripheral T-Cell Lymphoma (PTCL) in patients who have received at least one prior therapy

2. Treatment Regimen 

The recommended dose of romidepsin is 14 mg/m2 administered intravenously over a 4-hour period on days 1, 8, and 15 of a 28-day cycle. Cycles should be repeated every 28 days provided that the patient continues to benefit from and tolerates the drug.

3. AE/Warnings

Please see section 5 of the PI.

All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.